Influence of the alpha-adducin and ACE gene polymorphism on the progression of autosomal-dominant polycystic kidney disease

Kidney and Blood Pressure Research

Volumn 26, Issue 1, 2003, Pages 42-49

  Merta, Miroslav ^a,c   Reiterova J ^a   Stekrova J ^a   Rysava, R ^a   Rihova Z ^a   Tesar V ^a   Viklicky O ^b   Kmentova, D ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adducin polymorphism; ACE insertion deletion polymorphism; Autosomal dominant polycystic kidney disease; Progression

Indexed keywords

ADDUCIN; ALPHA ADDUCIN; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CZECH REPUBLIC; DISEASE COURSE; DNA DETERMINATION; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; GROUPS BY AGE; HOMOZYGOSITY; HUMAN; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; SEX RATIO;

ADULT; CALMODULIN-BINDING PROTEINS; DISEASE PROGRESSION; FEMALE; GENOTYPE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PHENOTYPE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; POLYMORPHISM, GENETIC;

EID: 0037262088     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000069768     Document Type: Article

References (56)

1. Ravine D, Walker RG, Gibson RN, Forrest SM, Richards RI, Friend K, Sheffield LJ, Kincaid-Smith P, Danks DM: Phenotype and genotype heterogeneity in autosomal dominant polycystic kidney disease. Lancet 1992;340:1330-1333.
2. Hateboer A, van Dijk MA, Bogdanova A, Coto E, Saggar-Malik AK, San Millan JL, Torra R, Breuning MH, Ravine D: Comparison of phenotypes of polycystic kidney disease types 1 and 2. Lancet 1999;353:103-107.
3. Peters DJ, Sandkuijl LA: Genetic heterogeneity of polycystic kidney disease in Europe. Contrib Nephrol. Basel, Karger, 1992, vol 97, pp 128-139.
4. Watnick T, Phakdeekitcharoen B, Johnson A, Gandolph M, Wang M, Briefel G, Klinger KW, Komberling W, Gabow P, Germino GG: Mutation detection of PKD1 identifies a novel mutation common to three families with aneurysms and/or very-early-onset disease. Am J Hum Genet 1999;65:1561-1571.
5. Peral B, Ong ACM, San Millan JL, Gamble V, Rees L, Harris PC: A stable, nonsense mutation associated with a case of infantile onset polycystic kidney disease 1. Hum Mol Genet 1996;5:539-542.
6. Hateboer N, Veldhuisen B, Peters D, Breuning MH, San-Millan JL, Bogdanova N, Coto E, van Dijk MA, Afzal AR, Jeffery S, Saggar-Malik AK, Torra R, Dimitrakov D, Martinez I, de Castro SS, Krawczak M, Ravine D: Location of mutations within the PKD2 gene influences clinical outcome. Kidney Int 2000;57:1444-1451.
7. Tanner GA, Tanner JA: Citrate therapy for polycystic kidney disease in rats. Kidney Int 2000;58:1859-1869.
8. Tanner GA, Vijayalakshmi K, Tanner JA: Effects of potassium citrate/citric acid intake in a mouse model of polycystic kidney disease. Nephron 2000;84:270-273.
9. Torres VE, Cowley BD Jr, Brandem MG, Yoshida I, Gattone VH: Long-term ammonium chloride or sodium bicarbonate treatment in two models of polycystic kidney disease. Exp Nephrol 2001;9:171-180.
10. Torres VE, Bengal R, Litwiller R, Wilson D: Aggravation of polycystic kidney disease in HAN:SPRD rats by buthionine sulfoximine. J Am Soc Nephrol 1996;8:1283-1291.
11. Nagao S, Yamaguchi T, Kasahara M: Effect of probucol in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 2000;35:221-226.
12. Torres VE, Bengal R, Nickander K: Renal concentration of alpha-tocopherol: Dependence on gender and lack of effect on polycystic kidney disease in Han:SPRD rats. Am J Kidney Dis 1998;31:687-693.
13. Tomobe K, Pholbrick D, Aukema H: Early dietary protein restriction slows disease progression and lengthens survival in mice with polycystic kidney disease. J Am Soc Nephrol 1994;5:1355-1360.
14. Ogborn M, Sareen S: Amelioration of polycystic kidney disease by modification of dietary protein intake in the rat. J Am Soc Nephrol 1995;6:1649-1654.
15. Tomobe K, Philbrick D, Ogborn M: Effect of dietary soy protein and genistein on disease progression in mice with polycystic kidney disease. Am J Kidney Dis 1998;1:55-61.
16. Ogborn M, Bankovic-Calic N, Shoesmith C: Soy protein modification of rat polycystic kidney disease. Am J Pathol 1998;274:F541-549.
17. Belibi FA, Wallace DP, Yamaguchi T, Christensen M, Reif G, Grantham JJ: The effect of caffeine on renal epithelial cells from patients with autosomal dominant polycystic kidney disease. J Am Soc Nehrol 2002;13:2723-2729.
18. Orth SR, Stockmann A, Donradt C, Ritz E, Ferro M, Kreusser W, Piccoli G, Rambausek M, Roccatello D, Schafer K, Sieberth HG, Wanner C, Watschinger B, Zucchelli P: Smoking as a risk factor for end-stage renal failure in men with primary renal disease. Kidney Int 1998;54:926-931.
19. Norman J, Badie-Dezfooly B, Nord EP, Kurtz I, Schlosser J, Chaudhari A, Fine LG: EGF-induced mitogenesis in proximal tubular cells: Potentiation by angiotensin II. Am J Physiol 1987;252:F299-309.
20. Harrap SB, Davies DL, Macnicol AM, Dominiczak AF, Fraser R, Wright AF, Watson ML, Briggs JD: Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int 1991;40:501-508.
21. Chapman AB, Johnson A, Gabow PA, Schrier RW: The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990;323:1091-1096.
22. Bell PE, Hossack KF, Gabow PA, Durr JA, Johnson AM, Schrier RW: Hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1988;34:683-690.
23. Barrett BJ, Foley R, Morgan J, Hefferton D, Parfrey P: Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. Kidney Int 1994;46:1118-1123.
24. Graham PC, Lindob GB: The anatomy of the renin-secreting cells in adult polycystic kidney disease. Kidney Int 1988;33:1084-1090.
25. Torres VE, Donovan KA, Scicli G, Holley KE, Thibodeau SN, Carretero OA, Inagami T, McAteer JA, Johnson CM: Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease. Kidney Int 1992;42:363-373.
26. Zeier M, Fehrenbach P, Geberth S, Mohring K, Waldherr R, Ritz E: Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int 1992;50:424-431.
27. Baboolal K, Ravine D, Daniels J, Williams N, Holmans P, Coles GA, Williams JD: Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease. Kidney Int 1997;52:607-613.
28. Perez-Oller L, Torra R, Badenas C, Milla M, Darnell A: Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease. Am J Kid Dis 1999;34:273-278.
29. Van Dijk MA, Peters DJM, Breuning MH, Chang PC: The ACE I/D polymorphism has no influence on progression of renal function loss in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2000;15:836-839.
30. Schiavello T, Burke V, Bogdanova N, Jasik P, Melsom S, Boudville N, Robertson K, Angelicheva D, Dworniczak B, Lemmens M, Horst J, Todorov V, Dimitrakov D, Sulowicz W, Krasniak A, Stompor T, Beilin L, Hallmayer J, Kalaydjieva L, Thomas M: Angiotensin-converting enzyme activity and the ACE Alu polymorphism in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2001;16:2323-2327.
31. Barber BR, Ferrari P, Bianchi G: The Milan hypertensive strain: A description of the model; in Ganten D, de Jong W (eds): Handbook of Hypertension. Amsterdam, Elsevier, 1994, pp 316-345.
32. Cusi D, Barlassina C, Azzani T, Casari G, Citterio L, Devoto M, Glorioso N, Lanzani C, Manunta P, Righetti M, Rivera R, Stella P, Troffa C, Zagato L, Bianchi G: Polymorphism of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997;349:1353-1357.
33. Castellano M, Barlassina C, Muiesan ML, Beschi M, Cinelli A, Rossi F, Rizzoni D, Cusi D, Agabiti-Rosei E: Alpha-adducin gene polymorphism and cardiovascular phenotypes in a general population. J Hypertens 1997;15:1707-1710.
34. Tamaki S, Iwai N, Tsujita Y, Nakamura Y, Kinoshita M: Polymorphism of alpha-adducin in Japanese patients with essential hypertension. Hypertens Res 1998;21:29-32.
35. Manunta P, Burnier M, D'Amico M, Buzzi L, Maillard M, Barlassina C, Lanella G, Cusi D, Bianchi G: Adducin polymorphism affects tenal proximal tubule reabsorption in hypertension. Hypertension 1999;33:694-697.
36. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, Siscovick DS, Bis J, Lumley T, Longstreth WT Jr, Rosendaal FR: Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002;13:1680-1689.
37. Schork NJ, Chakravarti A, Thiel B, Fornage M, Jacob HJ, Cai R, Rotimi CN, Cooper RS, Weder AB: Lack of association between a biallelic polymorphism in the adducin gene and blood pressure in whites and African-Americans. Am J Hypertens 2000;13:693-698.
38. Melander O, Bengtsson K, Orho-Melander M, Lindblad U, Forsblom C, Rastam L, Groop L, Hulthen UL: Role of the Gly460Trp polymorphism of the alpha-adducin gene in primary hypertension in Scandinavians. J Hum Hypertens 2000;14:43-46.
39. Nicod J, Frey BM, Frey FJ, Ferrari P: Role of the α-adducin genotype on renal disease progression. Kidney Int 2002,61:1270-1275.
40. Ravine D, Gibson RN, Walker RG, Sheffield LJ, Kincaid-Smith P, Danks DM: Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1. Lancet 1994;343:824-827.
41. Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucl Acids Res 1988;16:1215.
42. Bray MS, Li L, Turner ST, Kardia SL, Boerwinkle E: Association and linkage analysis of the alpha-adducin gene and blood pressure. Am J Hypertens 2000;13:699-703.
43. Rigat B, Hubert C, Corvol P, Soubrier F: PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DPC1) (dipeptidyl carboxypeptidase). Nucl Acids Res 1992;20:1433.
44. Shanmugam V, Sell KW, Saha BK: Mistyping ACE heterozygotes. PCR Methods Appl 1993;3:120-121.
45. Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, Inenaga T, Kimura G: Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet 1998;350:1734-1737.
46. Uemasu J, Nakaoka A, Kawasaki H, Ishikawa I, Yoshino Y, Shio H, Nemoto R, Nakamura I, Morio S: Association between angiotensin converting enzyme gene polymorphism and clinical features in autosomal dominant polycystic kidney disease. Life Sci 1997;60:2139-2144.
47. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F: An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-1346.
48. Tiret T, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F: Evidence from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992;51:197-205.
49. Zhu X, McKenzie CA, Forrester T, Nickerson DA, Broeckel U, Schunkert H, Doering A, Jacob HJ, Cooper RS, Rieder MJ: Localization of a small genomic region associated with elevated ACE. Am J Hum Genet 2000;67:1144-1153.
50. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW: Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000;35:427-432.
51. Keith DS, Torres VE, Johnson CM, Holley KE: Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han:SPRD rats. Am J Kidney Dis 1994;24:491-498.
52. Ruggenenti P, Perna A, Zoccali C: Chronic proteinuric nephropathies II. Outcomes and response to treatment in a prospective cohort of 352 patients: Differences between women and men in relation to the ACE gene polymorphism. J Am Soc Nephrol 2000;11:88-96.
53. Kleij FGH, Navis G, Gansevoort RT: ACE gene polymorphism does nor determine short-term renal response to ACE-inhibition in proteinuric patients. Nephrol Dial Transplant 1997;12:42-46.
54. Gonzalo A, Telleria D, San Millan JL, Ortuno J: Angiotensin converting enzyme gene polymorphism and antiproteinuric response to renoprotective therapy. Nephrol Dial Transplant 1998;13:1050-1051.
55. Ueda S, Meredith PA, Morton JJ: ACE I/D polymorphism as a predictor in response of the magnitude and duration of the response to an ACE inhibitor drug (enalapril) in humans. Circulation 1998;98:2148-2153.
56. Balrassina C, Schork NJ, Manunta P, Citterio L, Sciarrone M, Lanella G, Bianchi G, Cusi D: Synergistic effect of alpha-adducin and ACE genes causes blood pressure changes with body sodium and volume expansion. Kidney Int 2000;57:1083-1090.